Skip to main content
PMC home page
Sexually Transmitted Infections logoLink to Sexually Transmitted Infections
. 2003 Apr;79(2):137–141. doi: 10.1136/sti.79.2.137

A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals

R Power 1, H Tate 1, S McGill 1, C Taylor 1
PMCID: PMC1744634  PMID: 12690137

Abstract

Objectives: To investigate the psychosocial impact of lipodystrophy on the lifestyles of HIV positive patients on highly active antiretroviral therapy (HAART).

Methods: In-depth interviews were conducted with 14 HIV positive patients on HAART at an outpatient sexually transmitted infections (STI) and HIV clinic in central London. Qualitative data from interview transcripts were analysed using grounded theory to elicit key categories and subcategories.

Results: Three main themes relating to lipodystrophy emerged: effect on the individual; impact on the social world of the individual; responses of the individual. Lipodystrophy had physical and psychological effects, ranging from bodily discomfort to low self esteem and depression. Owing to its physical manifestations it was viewed as a visible marker of HIV disease. At the level of social functioning, lipodystrophy led to problems with personal and family relationships, although having a partner was protective. Individuals reported narrowing their social world, in some cases to degrees of social isolation. Individual responses included changes in diet, increased exercise regimes, steroid use and plastic surgery (mainly collagen injections to the face). For those who had experienced serious illness related to HIV, there was a more sanguine acceptance of lipodystrophy as an unfortunate consequence of longevity and drug therapy

Conclusions: Health professionals need to address the psychosocial implications of lipodystrophy, including the ways in which it may affect different groups and their adherence to therapy. Formative evaluations are needed to assess the potential for targeted interventions.

Full Text

The Full Text of this article is available as a PDF (136.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carr A., Samaras K., Thorisdottir A., Kaufmann G. R., Chisholm D. J., Cooper D. A. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999 Jun 19;353(9170):2093–2099. doi: 10.1016/S0140-6736(98)08468-2. [DOI] [PubMed] [Google Scholar]
  2. Chapman L. Body image and HIV: implications for support and care. AIDS Care. 1998 Jun;10 (Suppl 2):S179–S187. doi: 10.1080/09540129850124280. [DOI] [PubMed] [Google Scholar]
  3. Collins E., Wagner C., Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read. 2000 Sep;10(9):546–550. [PubMed] [Google Scholar]
  4. Dukers N. H., Stolte I. G., Albrecht N., Coutinho R. A., de Wit J. B. The impact of experiencing lipodystrophy on the sexual behaviour and well-being among HIV-infected homosexual men. AIDS. 2001 Apr 13;15(6):812–813. doi: 10.1097/00002030-200104130-00025. [DOI] [PubMed] [Google Scholar]
  5. Madge S., Kinloch-de-Loes S., Mercey D., Johnson M. A., Weller I. V. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS. 1999 Apr 16;13(6):735–737. doi: 10.1097/00002030-199904160-00020. [DOI] [PubMed] [Google Scholar]
  6. Marelich W. D., Johnston Roberts K., Murphy D. A., Callari T. HIV/AIDS patient involvement in antiretroviral treatment decisions. AIDS Care. 2002 Feb;14(1):17–26. doi: 10.1080/09540120220097900. [DOI] [PubMed] [Google Scholar]
  7. Martínez E., Garcia-Viejo M. A., Blanch L., Gatell J. M. Lipodystrophy syndrome in patients with HIV infection: quality of life issues. Drug Saf. 2001;24(3):157–166. doi: 10.2165/00002018-200124030-00001. [DOI] [PubMed] [Google Scholar]
  8. Palella F. J., Jr, Delaney K. M., Moorman A. C., Loveless M. O., Fuhrer J., Satten G. A., Aschman D. J., Holmberg S. D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar 26;338(13):853–860. doi: 10.1056/NEJM199803263381301. [DOI] [PubMed] [Google Scholar]
  9. Qaqish R. B., Fisher E., Rublein J., Wohl D. A. HIV-associated lipodystrophy syndrome. Pharmacotherapy. 2000 Jan;20(1):13–22. doi: 10.1592/phco.20.1.13.34667. [DOI] [PubMed] [Google Scholar]
  10. Roche Régis, Poizot-Martin Isabelle, Yazidi Claire Martin-El, Compe Emmanuel, Gastaut Jean-Albert, Torresani Janine, Planells Richard. Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS. 2002 Jan 4;16(1):13–20. doi: 10.1097/00002030-200201040-00003. [DOI] [PubMed] [Google Scholar]
  11. Schrooten W., Colebunders R., Youle M., Molenberghs G., Dedes N., Koitz G., Finazzi R., de Mey I., Florence E., Dreezen C. Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS. 2001 May 25;15(8):1019–1023. doi: 10.1097/00002030-200105250-00010. [DOI] [PubMed] [Google Scholar]
  12. Tate H., George R. The effect of weight loss on body image in HIV-positive gay men. AIDS Care. 2001 Apr;13(2):163–169. doi: 10.1080/09540120020027323. [DOI] [PubMed] [Google Scholar]
  13. Vamos M. Body image in chronic illness--a reconceptualization. Int J Psychiatry Med. 1993;23(2):163–178. doi: 10.2190/BLL4-EVAL-49Y3-4G66. [DOI] [PubMed] [Google Scholar]
  14. van der Valk M., Gisolf E. H., Reiss P., Wit F. W., Japour A., Weverling G. J., Danner S. A., Prometheus study group Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 2001 May 4;15(7):847–855. doi: 10.1097/00002030-200105040-00005. [DOI] [PubMed] [Google Scholar]

Articles from Sexually Transmitted Infections are provided here courtesy of BMJ Publishing Group

RESOURCES